Timothy Warbington - 24 Sep 2026 Form 4 Insider Report for CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ)

Reporting relationship: President & CEO, Director, 10%+ Owner
Issuer ticker: CELZ
Reported as of: 24 Sep 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 25 Sep 2026, 18:00:29 UTC
Prior SEC filing: 29 Jun 2023
Source filing: View source filing
Reporting owner signature: /s/ Timothy Warbington

Key filing fact

Timothy Warbington filed Form 4 for CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) on 25 Sep 2026.

Key facts

This page summarizes Timothy Warbington's Form 4 filing for CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 25 Sep 2026, 18:00.

Change

Previous filing in this sequence was filed on 29 Jun 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (2)

CIK 0001674492 Primary reporting owner

Warbington Timothy

Relationship: President & CEO, Director, 10%+ Owner
Address: 211 E. OSBORN ROAD, PHOENIX
Signature: /s/ Timothy Warbington
Signature date: 25 Sep 2026

CIK 0002106672

Creative Acquisition Corp.

Relationship: Director
Address: 2375 E. CAMELBACK RD SUITE 600, PHOENIX
Signature: /s/ Timothy Warbington, Chairman and CEO of Creative Acquisition Corp.
Signature date: 25 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CELZ transaction

Common Stock

Award

Transaction value
Shares: +1,000,000
Change %: +2865%
Price
Shares after: 1,034,904
Date: 24 Sep 2026
Ownership: By entity
Footnotes: F1, F2

CELZ transaction

Common Stock

Award

Transaction value
Shares: +1,000,000
Change %: +2865%
Price
Shares after: 1,034,904
Date: 24 Sep 2026
Ownership: By entity
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The shares of common stock were issued to Creative Acquisition Corp. ("CAC") pursuant to a Stock Purchase Agreement dated September 24, 2026 (the "SPA"), between CAC and the Issuer, pursuant to which the Issuer purchased 4,000,000 shares of common stock of BioDefense, Inc. ("BioDefense") from CAC for a purchase price consisting of $200,000 in cash and 1,000,000 shares of the Issuer's common stock. After giving effect to the transactions under the SPA, the Issuer owns 80% (16,000,000) of the outstanding shares of BioDefense and CAC owns 20% (4,000,000) of the outstanding shares of BioDefense. Timothy Warbington is the Chairman and Chief Executive Officer of CAC, indirectly owns all of its outstanding shares of capital stock, and beneficially owns the shares held by CAC.

Footnote F2

Amount of shares of the Issuer's common stock beneficially owned following the reported transaction consists of 12,209 shares owned by Timothy Warbington, 1,000,000 shares owned by CAC, and 22,695 shares owned by Creative Medical Health, Inc. ("CMH"). Mr. Warbington is the President of CMH, owns substantially all of its outstanding shares of common stock and beneficially owns the shares held by CMH.